Prostate Cancer Clinical Trials in New York, NY

Prostate Cancer Clinical Trials in New York, NY

View the best 10 prostate cancer medical studies in New York, New York. Access promising new therapies by applying to a New York-based Prostate Cancer clinical trial.

Trials in New York, New York

Here are the top 10 medical studies for prostate cancer in New York, New York

Image of Roswell Park Cancer Institute in Buffalo, United States.

Dietary Intervention +2 More

Procedure

Recruiting1 award10 criteria
This trial looks at whether giving nutrition and exercise advice to prostate cancer patients who are on androgen deprivation therapy can help to reduce obese frailty and change the levels of myokines in blood.
Image of UC San Diego Moores Cancer Center in La Jolla, United States.

Apalutamide +1 More

Antiandrogen

Recruiting1 awardPhase 3
This trial is testing if using apalutamide and hormone therapy around the time of surgery can help men with high-risk prostate cancer by reducing the hormones that help the cancer grow.
Image of University of Arizona Cancer Center-Orange Grove Campus in Tucson, United States.

Intensity-Modulated Radiation Therapy +1 More

Radiation

Recruiting1 awardPhase 2
This trial is studying niraparib as a possible treatment for prostate cancer. It is testing how well it works with standard treatments of radiation and hormonal therapy, and what the side effects are.
Image of USC Norris Comprehensive Cancer Center in Los Angeles, United States.

PC14586 +1 More

Small Molecule

Recruiting1 awardPhase 1 & 2
This trial is testing a new oral drug, PC14586 (rezatapopt), alone and with pembrolizumab, in patients with advanced cancers that have a specific genetic mutation. The drug aims to fix a mutated protein to help control cancer growth. The study will determine the best dose and evaluate the drug's safety and effectiveness.
Image of Alaska Clinical Research Center ( Site 0274) in Anchorage, United States.

Pembrolizumab +2 More

Checkpoint Inhibitor

Recruiting2 awardsPhase 3
This trial will test whether a combination of drugs is better than placebo at extending radiographic progression-free survival and overall survival for men with metastatic hormone-sensitive prostate cancer.
Image of NCT02257736 in Phoenix, United States.

Prednisone +2 More

Corticosteroid

Recruiting1 awardPhase 3
This trial tests apalutamide added to a standard treatment for advanced prostate cancer. It targets patients whose cancer has spread and who haven't had chemotherapy. The treatment works by blocking and lowering male hormones that help cancer grow. Apalutamide has shown efficacy in treating different stages of prostate cancer.
Image of University of South Alabama, Mitchell Cancer Institute ( Site 0065) in Mobile, United States.

Enzalutamide +1 More

Hormone Therapy

Recruiting1 awardPhase 3
This trial will test whether a combination of two drugs is better than one of the drugs alone at treating prostate cancer that has spread and is resistant to hormone therapy.
Image of Nebraska Cancer Specialists in Omaha, United States.

177Lu-PSMA-617 +2 More

Radioisotope Therapy

Recruiting2 awardsPhase 3
This trial tests if adding a radioactive drug to standard hormone treatments can better treat men with advanced prostate cancer. The drug targets and kills cancer cells with radiation, while standard treatments block hormones that help cancer grow.
Image of Princess Margaret Cancer Centre in Toronto, Canada.

Remote Monitoring of Patient Reported Outcomes

Behavioural Intervention

Recruiting1 award
This trial aims to improve the treatment process for breast and prostate cancer patients undergoing radiation therapy (RT). Patients often experience side effects from RT, and by allowing them to self-report these side effects using mobile
Image of Vancouver Prostate Centre in Vancouver, Canada.

Luteinizing hormone-releasing hormone agonist (LHRHa) +1 More

Hormone Therapy

Recruiting1 awardPhase 2
This trial will test whether a therapy based on the genomic testing of prostate tumour tissue will improve clinical response. Participants will be treated with LHRHa plus APA for 8 weeks while genome sequence characterization is done. Those with unevaluable tissue will remain on LHRHa plus APA for 16 weeks. Those with evaluable tissue will be assigned to one of three sub-studies and randomized to a specific treatment arm. The study will evaluate response rate and outcomes after radical prostatectomy.

Phase 3 Trials

Trials With No Placebo

View More Related Trials

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.